Avicine

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Avicine was originally developed by a biotech company called AviBiopharma. It was tested as an anti-cancer vaccine which an objective of stimulating an immune reaction to the tumor associated antigen human chorionic gonadotropin (hCG).

Research behind the drug[edit]

Avicine is a synthesized formulation of peptides that was originally developed and tested in the 1990s, to create an unstable environment for hCG-producing cancer cells. By joining peptides together with diphtheria toxoids, the Avicine formulation was designed to cause a specific immune response to hCG.

Common elements between pregnancy and cancer[edit]

During pregnancy, women naturally generate the hCG hormone which stimulates growth and protects the developing fetus from auto-immune attack, therefore making the pregnancy successful; some cancer cells are known to produce hCG also, and this was the hypothesis prompting several researchers to consider an anti-hCG vaccine in cancer treatment. In both Cancer and pregnancy hCG :

  • encourages rapid cell division
  • musters development/reaction and tissue invasion
  • promotes formation of blood vessels
  • Allows tumor or fetus to cancel rejection by suppressing the immune system

The hypothesis of an anti-hCG vaccine is to modulate an immune response against malignant cells.